These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 29483450

  • 21. Lapatinib and letrozole as first-line therapy for metastatic breast cancer: case report of bone metastasis 18 years later.
    Mariani G, Ricchini F, Sica L, Bianchi GV.
    Tumori; 2013; 99(6):264e-8e. PubMed ID: 24503800
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study.
    Martín M, Loibl S, von Minckwitz G, Morales S, Martinez N, Guerrero A, Anton A, Aktas B, Schoenegg W, Muñoz M, Garcia-Saenz JÁ, Gil M, Ramos M, Margeli M, Carrasco E, Liedtke C, Wachsmann G, Mehta K, De la Haba-Rodriguez JR.
    J Clin Oncol; 2015 Mar 20; 33(9):1045-52. PubMed ID: 25691671
    [Abstract] [Full Text] [Related]

  • 30. Preoperative carboplatin-paclitaxel-bevacizumab in triple-negative breast cancer: final results of the phase II Ca.Pa.Be study.
    Guarneri V, Dieci MV, Bisagni G, Boni C, Cagossi K, Puglisi F, Pecchi A, Piacentini F, Conte P.
    Ann Surg Oncol; 2015 Sep 20; 22(9):2881-7. PubMed ID: 25572687
    [Abstract] [Full Text] [Related]

  • 31. [A Case of HER2-Positive Breast Cancer Treated with Nipple-Sparing Mastectomywith Immediate Reconstruction Using a Tissue Expander after Nab-Paclitaxel Combined with Chemotherapy].
    Nonomura A, Aomatsu N, Tei S, Haraoka G, Tsujio G, Yamakoshi Y, Wang E, Nagashima D, Hirakawa T, Iwauchi T, Nishii T, Morimoto J, Nakazawa K, Uchima Y, Takeuchi K.
    Gan To Kagaku Ryoho; 2016 Nov 20; 43(12):2056-2058. PubMed ID: 28133220
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
    Duman BB, Afşar ÇU, Günaldi M, Sahin B, Kara IO, Erkisi M, Erçolak V.
    Asian Pac J Cancer Prev; 2012 Nov 20; 13(8):4119-23. PubMed ID: 23098527
    [Abstract] [Full Text] [Related]

  • 40. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
    Zielinski C, Láng I, Inbar M, Kahán Z, Greil R, Beslija S, Stemmer SM, Zvirbule Z, Steger GG, Melichar B, Pienkowski T, Sirbu D, Petruzelka L, Eniu A, Nisenbaum B, Dank M, Anghel R, Messinger D, Brodowicz T, TURANDOT investigators.
    Lancet Oncol; 2016 Sep 20; 17(9):1230-9. PubMed ID: 27501767
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.